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7Introductory note
Three in-depth reviews of topical interest are published as ‘Selected issues’ in conjunction with the annual report each year. 
These selected issues are based on information provided to the EMCDDA by the EU Member States and candidate countries 
and Norway (participating in the work of the EMCDDA since 2001) as part of the national reporting process.
The three issues selected for 2007 are: 
• Drugs and driving; 
• Drug use and related problems among very young people (under 15 years old);
• Cocaine and crack cocaine: a growing public health issue.
Online versions of the 2007 selected issues (in English) and summaries (in 23 languages) are available at: 
http://issues07.emcdda.europa.eu
The national reports of the Reitox focal points are available on the EMCDDA website 
(http://www.emcdda.europa.eu/?nnodeid=435).
The 2007 Annual report on the state of the drugs problem in Europe is available in 23 languages and may be found at 
http://annualreport.emcdda.europa.eu
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Prevalence of and patterns and trends 
in cocaine and crack cocaine use
In recent years, there has been considerable concern about 
cocaine use in some European countries in recreational settings 
(e.g. discos and clubs), among young people in general, and 
among current or former problematic opioid users and other 
marginalised groups (e.g. sex workers in some cities) (1).
Recreational or integrated users mainly snort cocaine in 
powder form (cocaine hydrochloride), whereas users within 
marginalised groups usually inject cocaine or use crack 
cocaine (2). In Europe, crack cocaine use seems to be stable 
at a low level and concentrated among certain marginalised 
subpopulations in some cities.
Surveys have found that some countries have seen a marked 
increase in cocaine use among young people since the mid-
1990s. In addition, targeted studies have observed very high 
levels of cocaine use in some recreational settings (discos and 
parties). This is supported by data on indicators of cocaine 
availability in Europe; for example, the number of seizures, 
and more particularly amounts seized, increased dramatically.
In a few EU Member States, the demand for treatment for 
cocaine use has increased substantially in recent years, 
and now even exceeds that for opioid treatment in some 
countries, cities and regions. Moreover, a substantial 
proportion of opioid users in treatment report cocaine as their 
secondary drug, which may be contributing to their problems 
and can complicate their care. In many countries, cocaine 
is also reported in the toxicological analysis of a high 
proportion of drug-related deaths, generally in combination 
with opioids and other substances.
Although most of the focus on cocaine use is on more general 
patterns of recreational use, there is concern that the drug may 
be becoming more popular among socially disadvantaged 
groups. Cocaine injecting and the use of crack cocaine are 
both associated with considerable health risks such as drug 
overdose and the transmission of infectious diseases. 
In addition, there is concern about the possibly serious 
longer-term health effects of cocaine use (e.g. cardiovascular, 
neurological and psychiatric problems). These problems 
may occur among chronic users, including those who are 
socially well integrated. Some of these health problems could 
be aggravated by the concomitant use of alcohol and other 
substances, a pattern of drug use that is increasingly common. 
The health problems associated with cocaine use can be 
acute, but chronic use can cause cardiovascular toxicity, 
and this risk is elevated when cocaine use is combined with 
additional risk factors. The role of cocaine in these chronic 
health problems is often not apparent and may go unreported.
Cocaine use among 
the general population
In many EU countries, and in Europe overall, cocaine is, after 
cannabis, the second most commonly used illicit substance 
among the general population, as self-reported in surveys. Use 
is not evenly distributed, but seems to concentrate particularly 
in some countries and in some settings and social groups.
Prevalence among all adults
An overall prevalence of 3.7 % of the total adult population 
(15–64 years) in EU Member States and Norway translates 
into at least 12 million Europeans who have used this drug 
at least once in their lifetime (3). Ever in lifetime experience 
(1)  ‘Marginalisation’ is a social concept made up of a number of indicators that tend to cluster, particularly among minority groups, such as poverty, 
unemployment, poor education and poor health. In this selected issue, the term is used to describe groups that are not marginalised by choice, but that ‘suffer 
from marginalisation and vulnerability’.
(2)  For an objective and scientifically sound description of cocaine and crack cocaine and other drugs see the EMCDDA drug profiles 
(http://www.emcdda.europa.eu/?nnodeid=25482). 
(3)  The average proportion was computed as the average of national prevalence rates weighted according to the population of the relevant age group in each 
country. Total numbers were computed by multiplying prevalence among the population concerned in each country and, in countries for which no information 
was available, imputing the average prevalence. Figures here are probably a minimum, as there could be some under-reporting.
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of cocaine is reported by more than 5 % of the total adult 
population (15–64 years) in three countries: Spain, Italy and 
the United Kingdom (4); in contrast, in half of EU countries the 
prevalence is lower than 1.2 %.
Use in the last year is reported by at least 4.5 million 
Europeans (1.3 % on average). In Spain, Italy and the United 
Kingdom, last year prevalence is more than 2 %, but in half 
of EU countries it is about 0.5 % or less (5).
Use in the last month may be considered an indicator of 
current use. It is estimated that around 2 million Europeans 
(0.6 % on average) have used cocaine in the last month (6), 
although it is possible that this figure is an underestimate (7).
However, national averages do not reflect the level of 
cocaine use among young people (mainly males) in urban 
areas, especially use related to certain lifestyles. For instance, 
in the United Kingdom (8), it is estimated that around 13 % 
of 16- to 29-year-olds who frequently visit pubs or wine bars 
reported using cocaine in the last year, compared with 3.7 % 
among less frequent visitors. Among 30- to 59-year-olds, the 
figures were 3.1 % and 1 % respectively.
Prevalence among young adults and by gender
The prevalence of use of cocaine, as of other drugs, is higher 
among young adults (15–34 years), with around 7.5 million 
young Europeans (5.3 % on average) estimated as having 
used it at least once in their lifetime. In six countries, ever in 
lifetime prevalence is 5 % or higher (Denmark, Germany, 
Spain, Italy, the Netherlands and the United Kingdom) (9), 
with a median prevalence among all EU Member States of 
2 %. In the last year, an estimated 3.5 million (2.4 %) young 
adults have used cocaine, with the highest prevalence levels, 
of over 3 %, being found in Spain, Italy and the United 
Kingdom (10). In the last month, 1.5 million young adults are 
estimated to have used the drug. This represents around 
1 % of the EU population aged 15 to 34, with the prevalence 
in Spain and the United Kingdom being over 2 % (11).
It is worth noting that among young males (15–34 years), the 
prevalence is even higher. Ever in lifetime prevalence in this 
group is estimated at over 10 % in Denmark, Spain and the 
United Kingdom, and in the same three countries last year 
prevalence levels are reported to be over 5 % (12).
The male to female prevalence ratio for last year use ranged 
between unity and 1:12 for all adults and unity and 1:18 
for young adults in different countries. Weighted averages 
for the EU as a whole suggest that, among adult users of the 
drug, there were 2.5 males for each female. In young adults, 
this ratio was similar, at 2.4.
Evidence of polydrug use in survey data
Cocaine users very often also use alcohol and tobacco and 
other illicit drugs, including cannabis and other stimulants, and 
can be considered polydrug users in many cases (13). 
At an overall population level, there is a positive relationship 
between last year prevalence of cocaine and cannabis use: 
countries where there is a higher prevalence of cannabis use 
in the last year also have a higher prevalence of cocaine use 
in the same time period (see Figure 1) (14). Different hypotheses 
can be put forward to explain this correlation. It appears that 
the phenomenon of cocaine use does not exist in isolation 
but, rather, if people are using one drug they have a higher 
probability of using another drug. Another possible explanation 
might be the existence of a common factor underlying use of 
both drugs, e.g. the amount of disposable income among young 
people (e.g. Ramful and Zhao, 2007), some type of personal 
characteristic (e.g. Van Ours, 2003) or some other factor.
The relationship between use of cocaine and use of other 
stimulants (ecstasy and amphetamines) is very weak. 
It might be related to the possible process of replacement 
of stimulants (see below).
Surveys cannot easily identify crack cocaine use as such 
users will probably not be included in the sample. But, as an 
illustration, ever in lifetime prevalence in 2005/06 surveys 
(4) See Table GPS-8 in the 2007 statistical bulletin.
(5) See Table GPS-10 in the 2007 statistical bulletin.
(6) See Table GPS-12 in the 2007 statistical bulletin.
(7)  Population surveys may underestimate drug use, especially the more problematic forms, as this group of users may have no permanent address, refuse to 
participate or be unwilling to disclose their use. On the other hand, in targeted surveys (e.g. at discos or parties) cocaine use is reported by a high proportion 
of interviewees, in some cases in large amounts, suggesting that cocaine users are willing to discuss their use provided the information remains confidential.
(8)  British Crime Survey (England and Wales) 2003/04. Frequent visitors to pubs or wine bars (more than three times a week in the last month) were compared 
with infrequent visitors (fewer than three visits per week).
(9) See Table GPS-9 in the 2007 statistical bulletin. 
(10) See Table GPS-11 in the 2007 statistical bulletin.
(11) See Table GPS-13 in the 2007 statistical bulletin.
(12) See Figure GPS-13 in the 2007 statistical bulletin.
(13) See Figure 15 in the 2006 annual report.
(14)  The overall Pearson correlation (r) is 0.75. The Czech Republic and France are exceptions to this general rule, and if they are excluded as outliers the 
correlation becomes higher (r  = 0.9).
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was 0.9 % in the United Kingdom (England and Wales) 
(0.2 % last year prevalence) and 0.6 % in Spain 
(0.2 % last year).
International comparisons of prevalence
Overall, among young adults in the EU, ever in lifetime 
prevalence of cocaine use is lower than that reported in 
Australia, Canada and the USA. However, at the national 
level Denmark, Spain, Italy and the United Kingdom (England 
and Wales) report higher figures than Australia (see Figure 2).
Among young people, estimates of last year prevalence 
are higher in Spain and the United Kingdom (England and 
Wales) than in the USA, although the EU average is clearly 
lower.
Recent data from general population surveys show an 
upward trend in cocaine use during the 1990s in many 
European countries (last year use among young adults aged 
15–34 years). This trend seems to be continuing in many 
reporting countries, although there are signs that it may be 
stabilising in the Member States with the highest prevalence 
levels (Spain and the United Kingdom). In Germany, Greece, 
the Netherlands and Finland, cocaine use appears to have 
stabilised or even decreased in recent years (15). However, in 
Denmark and Italy, a marked increase was again reported in 
the most recent surveys (2005 in each case).
A similar pattern can also be observed in the 15–24 age 
group, with a pronounced increase in Spain, a somewhat 
smaller increase in the United Kingdom, and smaller, but 
steady, increases and in general lower prevalence in France 
and Denmark (16).
In countries with longer series of data and higher 
prevalences, it is possible to analyse trends in subgroups of 
the population, mainly by age and gender, or by the period 
of time over which prevalence is estimated (lifetime, last 
year, last month). In general, these data show a much bigger 
increase in lifetime prevalence than in last year or last month 
prevalence. This could be interpreted as an increase in the 
number of people who have tried the drug once or a few 
times in their lives but did not remain ‘active users’, or even 
‘recreational users’. Analysis of Spanish and United Kingdom 
data by age group reveals that the largest increases occurred 
in the 15–34 age group, although in Spain the increase in 
recent years (since 2001) has continued only among 15- to 
24-year-olds. In these two countries, a bigger increase was 
generally observed for males, especially between 1999 and 
2001 in Spain and between 1998 and 2000 in the United 
Kingdom.
It has been argued that, in some European countries, 
cocaine may have displaced other stimulants (ecstasy and 
amphetamines). Survey series data support this hypothesis 
in the United Kingdom, and to some extent in Denmark and 
Spain, although not in Germany, France or Italy. If true, 
the reasons could be changes in fashion, perceived status 
and risk for each substance and/or possible changes in the 
market.
Problem cocaine use
Some countries have conducted studies that attempt to 
estimate the extent of ‘problem cocaine use’ (injection or long 
duration/regular use) (17), which is associated with significant 
health and social consequences (e.g. dependence, 
marginalisation, acute health problems). However, at 
present, there is not enough information available to derive 
trends in estimated problem cocaine use with any precision 
at the European level.
Estimates of the total population of problem cocaine users 
have been made in Spain and Italy, and in England, there 
Figure 1: Correlation between last year prevalence of cocaine use 
and cannabis use among all adults (15–64 years), 
measured by population surveys
Source:  Reitox national reports, taken from surveys, reports or scientific articles.
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(15) See Figure 7 in the 2007 annual report.
(16) See Table GPS-15 in the 2007 statistical bulletin.
(17)  The EMCDDA definition of problem drug use is ’injecting drug use or long-duration/regular use of opioids, cocaine and/or amphetamines’. Similarly, problem 
cocaine use is defined as its injecting use or long-duration/regular use.
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are estimates of the number of problem crack cocaine 
users (18). Statistical methods based on treatment and law 
enforcement data were used in an attempt to account 
for unobservable data on hidden populations. Spain 
estimated that in 2002 there were between 4.5 and 
6 problem cocaine users per 1 000 adult population 
(aged 15–64 years). In Italy, there were estimated to be 
between 2.9 and 4.1 problem cocaine users per 
1 000 adults in 2005. For 2004/05 (19), the estimated 
number of problem crack cocaine users in England was 5.7 
to 6.4 per 1 000 adult population. Of the nine government 
regions in England, London was estimated to have the highest 
prevalence (9.9 to 10.8 per 1 000) and the South East 
(which excludes London) the lowest (3.0–5.0 per 1 000).
(18) For more information on the studies, see Table PDU-2 in the 2007 statistical bulletin.
(19) The period 1 April 2004 to 31 March 2005.
Figure 2: Lifetime and last year prevalence of cocaine use among young adults (15–34 years) in Europe, Canada, Australia and the USA
NB:  Countries have been ordered according to lifetime prevalence of cocaine use.
   In the European countries, most surveys were conducted between 2001 and 2006, and the standard age range is 15 to 34 years. (In some countries the lower end may 
be 16 or 18 years.)
   The European average prevalence rate was calculated as the average of the national prevalence rates weighted by national population of 15- to 34-year-olds (2004, 
taken from Eurostat).
   In the USA, the survey was conducted in 2005, and the age range is 16 to 34 years (recalculated from original data).
   In Canada, the survey was conducted in 2004, and the age range is 15 to 34 years (recalculated from original data).
   For Australia, the survey was conducted in 2004, and the age range is 14 to 39 years (recalculated from original data).
  Variations in age ranges may slightly influence disparities between countries.
  See also Table GPS-9.
Sources:   USA: SAMHSA, Office of Applied Studies, National Survey on Drug use and Health (2005), 
(www.samhsa.gov and (http://oas.samhsa.gov/nhsda.htm#NHSDAinfo).
   Canada: Adlaf, E. M., Begin, P. and Sawka, E. (eds) (2005), Canadian Addiction Survey (CAS) — A national survey of Canadians’ use of alcohol and other drugs — 
Prevalence of use and related harms: detailed report. Ottawa: Canadian Centre on Substance Abuse.
   Australia: Australian Institute of Health and Welfare (2005), 2004 National Drug Strategy Household Survey —Detailed Findings. AIHW Cat. No PHE 66. Canberra: 
AIHW (Drug Statistics Series No 16).
  Europe: based on Reitox national reports (2006).
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The Netherlands has estimated the population of problem 
opioid users who use crack cocaine to be between 2.2 and 
4.3 per 1 000 adults in 2001. However, this estimate does 
not include problem cocaine users who do not use opioids.
Cocaine use among school students
Overall prevalence rates for cocaine use are generally very 
low among school students and always considerably lower 
than for cannabis. School surveys conducted in 28 countries 
in 2003 revealed that, in most countries, less than 2 % of 
15- to 16-year-olds had tried the drug (Figure 3). Higher 
prevalence estimates for ever in lifetime use were reported in 
France, the Netherlands and Portugal (3 %), Italy, the United 
Kingdom (4 %) and Spain (6 % in 2004 and 4 % in 2006). 
In 14 countries where school survey data are available for 
17- to 18-year-old school students, lifetime prevalence of 
cocaine use rises to 5 % in the Netherlands, 6 % in Italy and, 
significantly, to 19 % in Spain in 2004 — although this has 
fallen to 11 % in 2006 (20).
Prevalence appears to be linked with perceptions about 
availability and risk; for example, in the countries with the 
highest levels of cocaine use, school students more often 
perceive the drug to be easily available and their perceptions 
about the risks associated with cocaine use are generally lower. 
However, caution is required in interpreting these data because 
of the relatively small numbers of 15- to 16-year-olds who have 
ever tried cocaine in these ESPAD school surveys.
Trends in cocaine use among school children
Spanish national school surveys show a continuous increase 
in the prevalence of cocaine use over the past decade until 
the 2006 survey, which reports a decrease of more than 
3 percentage points between 2004 and 2006. ESPAD 
school surveys also show some increase in ever in lifetime 
prevalence of cocaine use among 15- to 16-year-old school 
students over the past decade, but caution is needed in 
drawing conclusions about increases of less than 3 
percentage points among school students because of the 
small numbers involved in some of the surveys (21).
(20)  Data on 17- to 18-year-old school students are nationally representative of that age group only in countries where the compulsory school leaving age requires 
school attendance to the age of 18 years.
(21) See Table EYE-3 in the 2007 statistical bulletin.
Figure 3: Lifetime prevalence of cocaine use among the 15–16 and 17–18 age groups
NB:   Countries are ordered by lifetime prevalence among the 17–18 age group.
   Data for 15- to 16-year-olds are based on ESPAD 2003 surveys except for Belgium, Spain and Sweden where data are based on national surveys conducted in 
2004.
   Data for 17- to 18-year-olds are based on national surveys reported by the Reitox network, generally using ESPAD methods. Among the 17-  to 18-year-olds, data from 
Latvia are based on a sample from Riga only.
Sources:  ESPAD and Reitox network in 2003 and 2004.
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Prevalence and patterns 
of use among specific populations
Site-sampling studies of cocaine users, conducted in locations 
that are commonly visited by individuals who take cocaine, 
are not representative in any statistical sense, but they do 
provide a useful window on ‘hidden’ drug use. These studies 
tend to focus on settings where problematic drug users or 
recreational drug users congregate. Problematic cocaine 
users, for example, may be found in drug treatment service 
settings, low-threshold services and street settings where 
drugs are bought and sold, while more socially integrated 
recreational users of cocaine congregate in dance music and 
other nightlife settings. The information that these site studies 
provide is valuable for developing and targeting prevention 
and risk reduction initiatives. One European study of 1 855 
cocaine users conducted in nine European cities (Barcelona, 
Budapest, Dublin, Hamburg, London, Paris, Rome, Vienna 
and Zurich) in 2002 and 2003 targeted three main categories 
of cocaine users: those attending drug treatment services; 
unemployed and marginalised cocaine users who were not 
attending drug treatment services; and individuals who use 
cocaine but are mainly employed and socially integrated. 
Some 86 % of all study participants had used cocaine powder 
during the 30 days prior to the interview and 27 % had used 
crack cocaine, but there were considerable variations between 
the cities and in patterns of use among the three groups.
This European nine-city study revealed that marginalised cocaine 
users displayed more problematic patterns of drug use than those 
attending drug treatment services — in terms of having the highest 
consumption of cocaine and crack cocaine use, the highest 
intensity of heroin use and injecting and the highest prevalence 
of polydrug use. These findings suggest that marginalised drug 
users who do not attend drug treatment services may adopt 
patterns of drug use that are more problematic than those who 
are receiving treatment (Prinzleve et al., 2004). Research among 
problem and marginalised drug users in Belgium has shown a 
progressive increase between 1994 and 2001 in the number of 
cocaine users, and that the combination of heroin and cocaine 
has become more popular than in the past. Six other countries 
report findings from studies of cocaine users not attending drug 
treatment services that broadly support the findings of the nine-city 
study (Ireland, France, Luxembourg, the Netherlands, Austria and 
the United Kingdom).
Three of the cities in the European city study (Hamburg, London 
and Paris) accounted for the majority of the crack cocaine users. 
However, crack cocaine has been reported to be a significant 
problem for users in three French overseas territories — 
Guadeloupe, Guyana and Martinique — and among 
marginalised groups in the Netherlands. In the United Kingdom, 
self-reported use of crack cocaine among sex workers has risen 
considerably in London and Liverpool over the past 15 years. 
The United Kingdom Home Office suggests that the sex and drug 
markets appear to be interconnected in the case of crack cocaine.
Integrated cocaine users are generally distinct from 
problematic and marginalised users in their patterns of 
cocaine use. The nine-city European study reported that most 
integrated cocaine users take the drug only occasionally, and 
one third had never used cocaine more than once a week. 
Furthermore, most were snorting cocaine powder rather 
than injecting it or smoking crack cocaine. Most site studies 
that target socially integrated young people in the EU focus 
on individuals who attend electronic dance music events. 
These studies consistently report much higher prevalences 
of cocaine use than are found in surveys of the general or 
school student population. In countries where surveys have 
been conducted in dance music settings, reported ever in 
lifetime prevalence of cocaine use has ranged from 10 % in 
Athens to over 60 % in France, Italy (Milan) and the United 
Kingdom. In general, last month prevalence of cocaine use 
is reported to be much lower (Figure 4). A 2005 survey of 
Amsterdam pub-goers reported that 8 % had used cocaine 
during the last 30 days (Nabben et al., 2006).
Prevalence of crack cocaine use is, generally, very low 
among individuals surveyed in dance music settings. 
The strong separation of the (mainstream) powder cocaine 
scene from the (marginalised and problematic) crack cocaine 
scene is supported by most studies. An illustration of this 
Figure 4: Prevalence of ever in lifetime and last 30 days use 
of cocaine in selected dance music populations
NB:    Estimates for selected recreational settings are based on non-probability samples 
using a variety of methods and sampling frames. Prevalence of drug use among 
the broader dance music population cannot be inferred from these samples.
 
Sources:   Reitox national reports; Korf (2004) et al.; McCambridge et al. (2005).
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is can be found in the 2004 United Kingdom clubbers’ 
magazine survey, in which 41 % of respondents reported 
that they had used cocaine powder in the month before 
the survey, but only 3.4 % had used crack cocaine during 
this time. However, the extent to which this sample is 
representative of all club-goers is unclear and respondents 
probably represent a group where regular drug taking is 
relatively common.
With regard to the quantities of cocaine that are consumed 
by cocaine users, data are limited and vary between studies. 
A United Kingdom clubbers’ magazine survey conducted in 
2005 reported that nearly 90 % of cocaine users reported 
taking half a gram or more in one session, and nearly 
half of these took 1 gram or more (Mitcheson, personal 
communication, 2006). While the respondents to this survey 
are self-selected and the reliability of self-reports cannot be 
assured, such high levels of reported consumption might be 
explained by factors such as the relatively high-status image 
of cocaine, promoting its conspicuous consumption; long club 
opening times, leading to long late-night sessions; combined 
use of alcohol and other drugs, which serves to ameliorate 
the acute effects of cocaine use and encourage heavy use; 
and easy access to cocaine by virtue of its ready availability 
and also an increase in disposable incomes.
An important factor to consider in relation to cocaine use by 
socially integrated young people is that recreational drug use is, 
in general, limited to periods away from work, study and family, 
such as at weekends or during holiday periods or celebrations 
(Bellis et al., 2003). Qualitative research studies suggest that 
even the more problematic patterns of use may be short-lived for 
a proportion of individuals (Belgian national report).
Some countries reported that cocaine is more likely than 
ecstasy to be used in private or work settings (Belgium, 
Ireland, Austria, Poland, Portugal and Norway). This suggests 
that site surveys conducted in dance music settings in the EU 
may prove less useful for developing and targeting cocaine 
prevention initiatives than they have been for ecstasy in the 
past. Furthermore, the average age at first cocaine use tends 
to be higher than for ecstasy and the physical manifestations 
of cocaine use less obvious to observers than they are for 
ecstasy and amphetamines (Norway; McCambridge et al., 
2005). Therefore, cocaine users may be more heterogeneous 
and hidden than ecstasy and amphetamine users and pose 
a greater challenge for policymakers wishing to target 
prevention and risk reduction initiatives.
Trends in cocaine use in recreational settings
Data on trends from research conducted in dance music 
settings are rare due to the limited capacity to make 
comparisons between different surveys over time. However, 
some countries have reported trends based on information 
from such studies. For example, the Austrian ChEckiT studies 
report a significant increase in the use of cocaine; a Czech 
dance club survey reported a small increase in cocaine 
use between 2000 and 2003; and a United Kingdom club 
magazine survey reported an increase in last month use of 
cocaine from 36 % in 1999 to 41 % in 2003 (McCambridge 
et al., 2005). A qualitative trend-watch study in the 
Netherlands and a drugs-monitoring study in Amsterdam 
conducted since 1994 suggest that the popularity of cocaine 
increased over the past decade but now appears to have 
stabilised.
At least 10 drug helplines in Europe report increases in 
calls about cocaine use in 2005 and 2006. Increases in the 
number of calls to helplines for advice about cocaine in recent 
years have been more marked than for any other substance 
apart from cannabis, which has also been subject to a marked 
increase in helpline contacts (FESAT, 2005 and 2006).
Problems related to cocaine 
and crack cocaine use
Treatment demand data
After opioids and cannabis, cocaine is the drug most 
commonly reported as the reason for entering treatment in 
Europe. Cocaine accounted for about 13 % of all treatment 
demands across the EU in 2005, corresponding to 
48 000 reported cases (22). Cocaine is also reported as 
a secondary drug by around 15 % of all drug outpatient 
clients (23). There is a wide variation between countries, 
with the Netherlands and Spain historically reporting high 
proportions of cocaine users among drug clients (35 % and 
41 % respectively in 2005), whereas most countries report 
rather low rates. According to the most recent data (from 
26 countries), excluding the Netherlands and Spain, more 
than half of the countries report that cocaine users account 
for less than 5 % of all drug clients and in the remaining 
countries they make up between 5 % and 21 % (24).
Available European data on drug users entering treatment for 
primary cocaine use are mainly related to cocaine powder 
(84 %), with only 16 % reporting use of crack cocaine (25).
(22) See Figure TDI-2 in the 2007 statistical bulletin.
(23) See Table TDI-22 (part i) in the 2007 statistical bulletin.
(24) See Table TDI-5 (part ii) in the 2007 statistical bulletin; for data on Spain refer to 2004.
(25) See Table TDI-115 in the 2007 statistical bulletin.
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The proportion of clients entering treatment for primary 
cocaine use for the first time in 2005 was higher than the 
proportion of all cocaine clients: overall around 22 % of all 
new treatment demands (33 000 individuals) are reported to 
be cocaine related (26). Out of 25 countries reporting data on 
new cocaine clients in 2005, the proportion of new cocaine 
clients was higher than the proportion of all cocaine clients in 
15 countries, the same 6 countries and lower in 4 countries, 
the Netherlands being among the last group (27).
The increasing trend in demand for cocaine treatment noted 
in previous years’ annual reports is continuing. Between 1999 
and 2005, the proportion of new clients demanding treatment 
for cocaine use grew from 10 % to 21 % of all new drug 
clients; the number of reported cases rose from 12 600 to 
33 000 (based on 20 EU countries for which data were available 
for the time period) (28). A similar increase was observed in the 
number of all reported cocaine clients (from 15 500 in 1999 
to 39 500 in 2005), although, as a proportion of all drug 
clients, this amounts to a much smaller increase: from 9 % 
to 13 % (29). Considering only those countries with at least 
100 cocaine users among drug clients, between 1999 and 
2005, the largest increases in new cocaine clients (proportion 
of all clients and absolute numbers) were reported by Italy 
and Spain. The rising trend in these European countries is 
in contrast with the trends in drug treatment demands in the 
United States, where rates of admission decreased by 24 % 
between 1992 and 2002 (DASIS, 2005).
The European increase in cocaine users entering treatment 
may be related to several factors, in particular increases in:
• prevalence of cocaine use and related problems, 
including an increase in the number of people with a long 
duration of cocaine use;
• referrals to treatment;
• number of polydrug users consuming several substances, 
including cocaine;
• treatment availability and range of treatment 
interventions;
• number of opioid users (including some in substitution 
treatment) also taking cocaine.
An increased number of cocaine clients are reported to 
experience physical, social and psychological problems 
related to cocaine use. An Irish follow-up study conducted 
in local communities in 2006 reported a deterioration in the 
general health of clients with problematic cocaine use; an 
increase in financial problems and engagement in criminal 
activities was also described (Drugnet Ireland, 2007). Several 
countries also report an increase in hospital psychiatric 
admissions and psychiatric disorders linked to cocaine use.
Some countries report an increase in the number of referrals 
from the criminal justice system and from family and health 
and social services. In Italy, between 2000 and 2004, the 
proportion of referrals to drug treatment from the criminal justice 
system that were attributed to cocaine use increased from 6 % 
to 10 %. Several countries mention that an increasing number 
of adolescents or very young people are consuming cocaine 
and exhibiting a change in their behaviour as a result; this might 
have led families and social networks to refer users to treatment.
There is increasing concern that cocaine may be 
complicating the treatment of those with opioid problems, for 
example by destabilising the behaviour of substitution clients.
Finally, increased drug treatment availability and a wider 
range of treatments on offer, including programmes targeted 
to specific user groups, including cocaine users, may have 
augmented the demand for cocaine treatment.
Cocaine clients largely enter treatment in outpatient centres 
(94 %) (30), but it has to be considered that the countries 
with the highest proportion of cocaine users in treatment 
(Spain, Italy and the Netherlands) do not report data on 
inpatient centres; furthermore, European national information 
systems often do not include private clinics treating cocaine 
users. Indeed, some studies report a tendency among 
problematic cocaine users to seek assistance from residential 
treatment rather than community-based treatment (Neale 
and Robertson, 2004). The following description of cocaine 
clients therefore refers only to outpatient treatment clients.
Cocaine clients (powder cocaine and crack cocaine clients) 
are reported to be the oldest drug clients after opioid users, 
with a mean age of 30 to 31 years. Some 64 % of cocaine 
clients are in the 20- to 34-year-old age group and 15 % are 
aged between 35 and 39 years (31).
Gender ratios of cocaine clients are among the highest for 
primary users of any drug, with 4.7 males for every female 
among all cocaine clients and 5.8 males for every female 
among new clients. As for the other drugs, gender ratios vary 
between countries (32).
(26) See Figure TDI-2 in the 2007 statistical bulletin.
(27) See Tables TDI-4 and TDI-5 in the 2007 statistical bulletin.
(28) See Figure TDI-1 (part i) and (part ii) in the 2007 statistical bulletin.
(29) See Figure TDI-3 (part i) and (part ii) in the 2007 statistical bulletin.
(30) See Table TDI-24 in the 2007 statistical bulletin.
(31) See Table TDI-10 in the 2007 statistical bulletin.
(32) See Table TDI-21 in the 2007 statistical bulletin.
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Most cocaine users treated in outpatient settings reported 
first using the drug between the ages of 15 and 24 years 
(mean age 22 years) (33). They mainly take the drug by 
snorting (46 %) or smoking (34 %), although 9 % of cocaine 
clients inject the drug (5 % among new clients) (34). Half of all 
cocaine clients use the drug occasionally (once a week or 
less often) and the other half take it regularly (several times 
a week or daily). A higher percentage of cocaine clients 
new to treatment use the drug regularly. However, there are 
considerable differences between countries in patterns of 
cocaine use: in the Netherlands, 51 % of cocaine clients take 
the drug daily, compared with only 12 % of cocaine clients 
in Germany; in Italy, of the 56 % of cocaine clients who 
report their frequency of use, 44 % are occasional users, in 
contrast to 16 % in Spain (35).
Cocaine is often used in combination with another illicit or 
licit subsidiary drug. The most common combinations are 
of two substances. Clients in treatment for cocaine as their 
primary drug most often report using it in combination with 
cannabis (28 %), alcohol (23 %) or opioids (16 %). Among 
clients in treatment for the primary use of another drug, 
cocaine is reported as a secondary drug by 22 % of opioid 
clients, 15 % of cannabis clients and 10 % of amphetamine 
or ecstasy clients (36).
Drug users entering treatment for problems related to cocaine 
can be divided into three groups:
• powder cocaine users, using the drug on its own or in 
combination with cannabis and/or alcohol;
• crack cocaine users, often using crack cocaine in 
combination with other drugs including heroin;
• polydrug users, including use of powder cocaine 
and heroin.
The first group is represented by the drug clients who use 
powder cocaine alone or in combination with cannabis 
(38 %) and/or alcohol (28 %). They are mainly males 
(gender ratio 6:1) (37) and are often referred to treatment by 
the criminal justice system or self-refer as a result of pressure 
from social and family networks. This group is reported to 
be socially well integrated, with stable living conditions and 
regular employment. A Dutch analysis of treatment data 
reports that clients in treatment for use of powder cocaine 
alone or in combination with alcohol or ‘soft’ drugs usually 
have an income from a regular job and live in their own 
apartment or with their family (SIVZ/IVZ, 2006).
The second group of cocaine clients is represented by 
those using crack cocaine, often in combination with other 
drugs, mainly opioids (38 %), cannabis (26 %) and alcohol 
(21 %) (38). Compared with drug clients using powder 
cocaine, women account for a higher proportion of crack 
cocaine clients (male to female ratio of 2.8:1 compared 
with 6:1) (39). A total of 8 000 drug clients are reported to 
have entered treatment for primary use of crack cocaine in 
2005 in 20 European countries, representing only 2.5 % 
of all European drug clients (40). However, crack cocaine 
users may pose particular challenges for treatment services, 
as they tend to have a more problematic drug history and 
a more marginalised social profile than users of powder 
cocaine. Crack cocaine clients are often homeless, many of 
them are unemployed or with precarious labour conditions, 
and some of them are engaged in sex work. A considerable 
proportion of drug clients entering treatment for primary 
crack cocaine use belong to ethnic minorities. Crack cocaine 
users also commonly live in large cities, often in specific 
neighbourhoods.
The third group of cocaine users is represented by users who 
consume cocaine in combination with heroin. Typically, 
they are either former heroin users receiving substitution 
treatment and now experiencing problems related to cocaine 
use or current heroin users, combining heroin with cocaine 
consumption (41). Local studies of drug injectors suggest that, 
in some areas, the combination of heroin and cocaine within 
an injection is becoming more popular (sometimes referred 
to by drug injectors as ‘speedballing’). European treatment 
demand data show that opioids are used as a subsidiary 
drug by 26 % of cocaine clients in France, 19.5 % in the 
Netherlands and 18 % in Italy; among clients reporting 
primary use of opioids, 53 % in the Netherlands, 37 % in 
Italy, 27 % in France and 21 % in Ireland report also using 
powder cocaine (42). While national studies also show that 
cocaine and heroin users are the major group of cocaine 
users in treatment, this group has shown a smaller relative 
increase since 2000 compared with users of cocaine 
powder, alone or with cannabis.
(33) See Table TDI-11 (part iii) in the 2007 statistical bulletin.
(34) See Table TDI-17 (part ii) and (part vi) in the 2007 statistical bulletin.
(35) See Tables TDI-18, TDI-111 and TDI-112 in the 2007 statistical bulletin.
(36) See Tables TDI-22 and TDI-23 in the 2007 statistical bulletin.
(37) See Table TDI-120 in the 2007 statistical bulletin.
(38) See Table TDI-118 in the 2007 statistical bulletin.
(39) See Table TDI-120 in the 2007 statistical bulletin
(40) See Tables TDI-2 and TDI-115 in the 2007 statistical bulletin.
(41) See Tables TDI-22 and TDI-23 in the 2007 statistical bulletin.
(42) See Table TDI-118 in the 2007 statistical bulletin.
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Cocaine-related offences
Overall at EU level, the number of ‘reports’ (43) of drug law 
offences that involve cocaine increased by an average (44) 
of 62 % between 2000 and 2005. Data show increasing 
trends in all reporting countries except Germany, where such 
offences remained relatively stable, and Bulgaria, where they 
decreased over the period (Figure 5).
The proportion of drug offences involving cocaine ranged 
in 2005 from 1 % or less in Lithuania, Poland and Slovakia 
to over 19 % in Spain, Italy and Luxembourg. Over the 
period 2000–05, this proportion increased in most reporting 
countries, while it remained stable in Bulgaria, Lithuania and 
Malta and decreased in Germany (45).
Seizures and market information
Production and trafficking of cocaine
Colombia is by far the largest source of illicit coca in the 
world, followed by Peru and Bolivia. Following a slight 
decrease in 2005 (from 1 008 tonnes in 2004), potential 
global production of pure cocaine, estimated by UN sources, 
remained stable in 2006 at 984 tonnes (980 tonnes in 
2005), of which Colombia contributed 62 %, Peru 28 % and 
Bolivia 10 % (UNODC, Government of Bolivia, Government 
of Colombia and Government of Peru, 2006; UNODC, 
2007).
Most of the cocaine seized in Europe comes directly from 
South America (mainly Colombia) or via Central America 
and the Caribbean. In 2005, Argentina, Brazil, Venezuela, 
Peru, Surinam, Ecuador, the French and the Dutch Antilles 
and Mexico were reported as transit countries for the cocaine 
seized in Europe (Reitox national reports, 2006). Cocaine 
from South America to Europe is increasingly trans-shipped 
via Africa (mostly western and central Africa), in particular 
through countries surrounding the Gulf of Guinea (Benin, 
Cape Verde, Ghana, Guinea-Bissau, Nigeria and Togo) 
(INCB, 2007a).
The main points of entry in Europe remain Spain, Portugal 
and the Netherlands, and, to a lesser extent, Belgium, 
Germany, France and the United Kingdom. Spain and the 
Netherlands continue to play a major role as distribution 
points for the cocaine entering Europe. However, other 
transit countries are reported in Europe, such as France, 
Germany, Italy, Bulgaria and Russia (Reitox national 
reports, 2006).
Seizures
Cocaine is the most trafficked drug in the world after herbal 
cannabis and cannabis resin. Global seizures of cocaine 
continued to increase in 2005, reaching 755 tonnes. 
The largest quantities were intercepted in South America 
(Colombia, Venezuela and Ecuador), followed by North 
America (the United States and Mexico) (UNODC, 2007).
(43)  The term ‘reports’ for drug law offences is given in quotation marks because it describes different concepts in different countries (police reports of suspected 
drug law offenders, charges for drug law offences, etc.). For an exact definition for each country, refer to the methodological notes on drug law offences in the 
2007 statistical bulletin.
(44) Weighted by population size. See Figure DLO-6 in the 2007 statistical bulletin.
(45) See Table DLO-8 in the 2007 statistical bulletin.
Figure 5:   Cocaine-related offences in Europe, 2000–05
(1)  Persons given a summary fine by the prosecutor or sentenced by a court.
(2)   2002 data refer only to police data, while after-2002 data refer to all data reported 
by the main law enforcement authorities (police, gendarmerie and customs).
(3)   Offences for cocaine only — this does not include offences for ‘cocaine and other 
drug(s)’. Since the decriminalisation of drug use/possession for use in July 2001, 
such offences are reported through a different monitoring system; although data 
from the latter are taken into consideration here (from mid-2001 onwards), caution 
is required when comparing data from before and after 2001. (It should also be 
noted that the new information system on offences for drug use/possession was 
being tested for the first time.)
(4)  Arrests for presumed offences against the 1973 drug law.
NB:   Data between brackets refer to the number of reports for cocaine-related offences 
in 2005, except for France (2004), Sweden (2004) and the United Kingdom 
(2004).
  Data were not available for Denmark, Estonia, Latvia, Hungary, the Netherlands, 
Romania, Finland and Norway.
  United Kingdom: 2001 data refer only to England, Scotland and Wales. Data do 
not include crack cocaine.
 See Figure DLO-4 in the 2007 statistical bulletin for further information.
Sources:  Reitox national focal points.
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In 2005, an estimated 70 000 seizures of 107 tonnes of 
cocaine were made in Europe. Most seizures continue to 
be reported in west European countries, especially Spain, 
which has accounted for about half the seizures and amounts 
of cocaine recovered in Europe in recent years (46). Over 
the period 2000–05, both the number of cocaine seizures 
and quantities seized increased overall at European level, 
with particularly marked increases in recent years in Spain 
and Portugal, reflecting the trafficking routes of cocaine. In 
2005, Portugal, for the first time, overtook the Netherlands in 
intercepting the largest quantities of cocaine after Spain.
Price and purity
In 2005, the average or typical retail price of cocaine varied 
widely across Europe, from EUR 45 per gram in Poland to 
over EUR 100 per gram in Cyprus, Romania and Norway, 
with most countries reporting prices between EUR 50 and 
EUR 80 per gram (47). The mean prices of cocaine, corrected 
for inflation, showed an overall downward trend over the 
period 2000–05 in most reporting countries (48).
Compared with heroin, the average or typical purity of 
cocaine at user level is high, varying in 2005 between 24 % 
and 78 % in Europe, with most countries reporting purities of 
between 30 % and 60 % (49). Data available over 2000–05 
indicate an overall decrease in the mean purity of cocaine in 
most reporting countries.
Deaths related to cocaine
Cocaine deaths are more difficult to define and identify than 
deaths due to opioid overdose. Cocaine-related fatalities 
are multifactorial, and often the exact cause is difficult to 
determine. Deaths from purely pharmacological overdose 
seem to be infrequent, except in the case of massive 
exposure (e.g. in drug couriers carrying cocaine internally), 
with most cocaine deaths being the result of chronic toxicity 
leading to cardiovascular (such as arrhythmias, myocardial 
ischaemia and infarction) and neurological complications 
(such as haemorrhagic or ischaemic stroke) (Ghuran and 
Nolan, 2000; Kaye and Darke, 2004; Steven and Karch, 
1999; Vasica and Tenant, 2002).
Deaths related to cocaine are not dose specific, and although 
some deaths have been reported after a single dose of a few 
hundred milligrams, there are cases in which a dose of several 
grams has not proved fatal. In addition, deaths can occur 
regardless of route of administration; although the risk is 
higher when the drug level increases rapidly in the brain (e.g. 
injection), deaths occur also with non-injecting routes of use.
Many cocaine deaths resulting from cardiovascular 
complications occur in people with pre-existing risk factors 
or conditions induced by chronic cocaine use, such as left 
ventricular hypertrophy, coronary atherosclerosis or vascular 
malformations in the brain, whose rupture can be caused 
by drug-induced hypertension (see below). For instance, 
an Australian study found high levels of cardiovascular and 
cerebrovascular pathology in the pathological examination 
of cocaine deaths (Darke et al., 2005).
Depending on how those deaths are investigated and 
recorded, they may not be identified as cocaine-induced 
deaths. It is necessary to improve investigation of deaths and 
health problems that could be related to cocaine use 
(e.g. younger people presenting at emergency medical 
services with cardiovascular pathology). Furthermore, it 
would be of great value to assess the true overall and cause-
specific mortality among cocaine users, for instance through 
mortality follow-up studies.
Cocaine overdose victims often recover spontaneously, 
as the effects of cocaine are brief because of the short 
half-life of the drug. In fatal cases, cocaine overdoses 
are characterised by acute physical and psychological 
symptoms with an accelerated onset and progression 
(frequently in a few minutes), manifesting in three phases: 
a first phase with early stimulation of the central nervous 
system (CNS) and high blood pressure and heart rate; 
a second phase with advanced CNS stimulation that 
may include malignant encephalopathy and generalised 
seizures, hypertension and cardiac arrhythmias; and a third 
phase leading to coma and loss of vital functions. Excited 
delirium is a common presentation of cocaine overdoses 
leading to death (about 10 %) (Sztajnkrycer and Baez, 
2005), although this condition can occur also with other 
stimulants, in schizophrenic patients and in patients taking 
neuroleptic medication.
The risk of cocaine toxicity seems to be influenced by 
concomitant use of other substances, in particular alcohol 
(46)  This should be checked against missing 2005 data when available. See Tables SZR-9 and SZR-10 in the 2007 statistical bulletin. For estimating purposes, 
2005 missing data were replaced by 2004 data.
(47) See Table PPP-3 in the 2007 statistical bulletin.
(48) Cocaine price trends over the period 2000–05 were available in 19 European countries (data available for at least three consecutive years).
(49) See Table PPP-7 in the 2007 statistical bulletin.
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and heroin (see boxes ‘Cocaine and alcohol’ and ‘Cocaine 
and heroin’). This is a general phenomenon in overdose 
deaths, where polydrug use seem to increase the risk.
In Europe, generally, overdose deaths involving both 
opioids and cocaine (and generally other substances) are 
considered as opioid deaths, as deaths caused by the use 
of illicit substances in the absence of opioids are relatively 
infrequent. It has been suggested that cocaine may increase 
the risk of overdose death among opioid users, as cocaine 
also induces respiratory depression (Jaffe, 1990; Platt, 
1997; Tseng et al., 1991). In Europe, cocaine is often 
found together with heroin in overdose deaths (EMCDDA, 
2006a), which may reflect the high level of polydrug use 
among problematic drug users.
In both 2005 and 2006, the 2006 Reitox national reports 
identified over 400 deaths as cocaine related. However, in 
many cases it was difficult to ascertain whether the death was 
due primarily to cocaine poisoning, or whether it was due 
to a combination of substances or the result of a pre-existing 
health problem precipitated by cocaine use. Following a field 
trial to improve information on substances involved in drug 
deaths, several countries have improved their reporting, but 
further work is still necessary.
It remains unclear how cocaine deaths are identified and 
classified in Europe. In particular, it is possible that deaths 
occurring shortly after, and induced by, cocaine use, but 
which are not poisonings in the strict sense (e.g. deaths due 
to acute myocardial infarctions, arrhythmias or stroke), are 
not identified as induced by cocaine, and therefore are not 
reported.
Medical problems related to cocaine use
Cocaine use has been associated with a variety of medical 
complications, which may involve all major organs or 
systems. Such complications can be associated with acute 
and chronic cocaine use and may differ according to the 
route of administration. Polydrug use, involving mainly 
heroin, alcohol and cannabis, is the predominant pattern 
of cocaine use in Europe. This, together with the various 
impurities and cutting agents often found in ‘street’ cocaine, 
may increase the adverse health effects (see boxes ‘Cocaine 
and alcohol’ and ‘Cocaine and heroin’).
Acute and chronic cocaine use can cause:
• cardiovascular disorders;
• cerebrovascular disorders and neurological impairment;
• respiratory disorders, either acute (pulmonary oedema, 
pulmonary infarction, haemoptysis) or chronic 
(e.g. pulmonary hypertension);
• genitourinary and obstetric disorders, either acute 
(acute renal failure, mediated by rhabdomyolysis (50) or 
direct toxicity, testicular infarction, placental abruption, 
spontaneous abortion) or chronic (premature birth, 
growth retardation);
• gastrointestinal complications (mesenteric ischaemia or 
infarction);
(50) Rhabdomyolysis is the breakdown of muscle fibres resulting in the release of muscle fibre contents into the circulation.
Cocaine and alcohol
The combination of alcohol and cocaine is popular among 
drug users, perhaps because of the more intense feelings of 
‘high’ achieved, beyond that perceived with either drug alone. 
In addition, cocaine makes the effect of alcohol inebriation less 
intense and alcohol tempers the discomfort felt when coming 
down from a cocaine ‘high’ (Pennings et al., 2002). Some 
users take cocaine at the same time as alcohol to enable them 
to drink for longer, which may also have the effect of increasing 
the amount of cocaine consumed (Gossop et al., 2006).
Prospective studies show that simultaneous consumption of 
cocaine and alcohol increases heart rate with a greater than 
additive effect, as well as increasing systolic blood pressure and 
impairment of cognitive and motor functions (Pennings et al., 
2002). Furthermore, compared with cocaine alone, concomitant 
consumption of cocaine and alcohol increases blood levels of 
cocaine by up to 30 % (Farré et al., 1993; Gossop et al., 2006; 
McCance-Katz et al., 1993; Perez-Reyes and Jeffcoat, 1992). 
However, retrospective studies suggest that combined use does 
not cause more cardiovascular problems than expected from the 
additive effects of each drug (Pennings et al., 2002).
Importantly, the concomitant use of alcohol and cocaine results 
in the formation of a new substance, cocaethylene (Rafl a and 
Epstein, 1979), a pharmacologically active metabolite synthesised 
in the liver (Brzezinski et al., 1994). There is some controversy as 
to whether cocaethylene or alcohol-induced increases in cocaine 
levels are responsible for the increased heart rate, and presumed 
increased cardiotoxicity, arising from alcohol and cocaine 
combinations. Because of its pharmacological properties, such as 
slower clearance, longer elimination half-life and larger volume of 
distribution, cocaethylene persists longer in body fl uids and tissues, 
and thus high blood levels are present in post-mortem studies. This 
has led previous researchers to conclude that it has higher toxic 
potency than cocaine (Lepere and Charbit, 2002). Cocaethylene 
produces cocaine-like cardiovascular and subjective effects, but 
discrimination of its effects from the direct synergistic effects of the 
cocaine–alcohol combination is diffi cult. Cocaethylene, however, 
appears to be less potent than an equivalent dose of cocaine (Hart 
et al., 2000; McCance et al., 1995; McCance-Katz et al., 1993).
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• psychiatric disorders (euphoria, dysphoria, agitation, 
anxiety, suicidal thoughts, paranoid psychosis, 
depression); and
• musculoskeletal and dermatological disorders.
The most common adverse health consequences are 
cardiovascular disorders, cerebrovascular disorders and 
neurological impairments, which may be associated with 
both acute and chronic cocaine use (Egred and Davis, 
2005). For this reason, the focus will be placed on these 
health problems, as an exhaustive review of all health 
consequences is not possible in this selected issue.
Cardiovascular disorders
The most common cardiovascular disorders related to 
cocaine are ischaemia and acute coronary syndrome, 
which can occur with all routes of cocaine intake. Other 
cardiac problems include arrhythmias, myocarditis and 
cardiomyopathy (Egred and Davis, 2005).
Chest pain is the most common symptom in cocaine users; 
however, only a small proportion (6 %) of cocaine-associated 
chest pain is attributable to myocardial ischaemia or 
myocardial infraction (Egred and Davis, 2005; Pozner et 
al., 2005). Cocaine users who present with acute chest 
pain may actually have acute myocarditis, rather than acute 
myocardial infarction. Myocarditis induced by cocaine may 
be either a toxic myocarditis, which is dose-dependent, or 
hypersensitivity myocarditis, which is not related to dose. 
In the event that the chest pain is non-ischaemic, many cases 
may result from an extracardiac cause such as barotraumas 
(e.g. pneumothorax and pneumoperitoneum) related to 
cocaine smoking or inhalation (Pozner et al., 2005).
Although most cases of cocaine-associated chest pain are 
non-ischaemic, myocardial infarction remains the single most 
frequently reported cardiac complication of cocaine use. Acute 
cocaine use, but also occasional use and long-term use, have 
been implicated as a trigger of acute myocardial infarction 
in patients free from coronary artery disease (Mouhaffel et 
al., 1995) and more frequently in patients with underlying 
coronary atherosclerosis, where the risk of myocardial 
infarction may be increased by as much as 24 times over 
baseline in the first hour after cocaine administration, but it 
could still be high as late as a few days afterwards (Mittleman 
et al., 1999). There is no clear relation between the dose of 
cocaine and the occurrence of an acute coronary event.
Cardiac arrhythmia may be life threatening and requires 
prompt treatment. A wide range of arrhythmias have been 
reported to be associated with cocaine use. These conditions 
are usually transient and resolve when cocaine is metabolised.
Endocarditis, or inflammation of the internal lining of the heart 
chambers and heart valves (endocardium), has been associated 
with intravenous injection of many illicit drugs, including cocaine 
(Chambers et al., 1987). However, cocaine use seems to be 
a greater independent risk factor for developing endocarditis 
than the use of other drugs. Furthermore, intravenous injection 
of cocaine may present an additional, independent risk for the 
development of endocarditis. It is presumed that the increases in 
heart rate and blood pressure that result from cocaine use may 
lead to valvular and vascular injury that predisposes to bacterial 
invasion, and the immunosuppressive effects of cocaine may 
also increase the risk of infection (Egred and Davis, 2005; 
Pozner et al., 2005).
Aortic dissection is a potentially life-threatening condition in 
which there is bleeding into and along the wall of the aorta, 
the major artery leaving the heart. Cocaine use can cause 
both acute and chronic dissection of the aorta (Brownlow and 
Pappachan, 2002). The use of cocaine can lead to acute 
aortic dissection, probably resulting from the severe 
transient increase in systemic arterial pressure caused 
by cocaine.
Atherosclerosis (accumulation of fatty materials along the 
walls of arteries which may eventually block the arteries) has 
been linked to chronic cocaine use. Cocaine directly induces 
Cocaine and heroin
An increasing number of drug users in Europe report dual 
dependence on cocaine and heroin (EMCDDA, 2006a). 
Opioid users who also use cocaine may take the drugs 
simultaneously or separately. Among drug users, the 
simultaneous injection of heroin and cocaine is often referred 
to as ‘speedballing’. In this case, the cocaine is either injected 
in a mixture with heroin or is injected immediately before or 
after the heroin, sometimes without removal of the syringe. 
Heroin users often report co-use of cocaine in a sequential 
manner either to enhance euphoria or to reduce the withdrawal 
symptoms commonly experienced during a typical day or 
when attempting self-detoxifi cation from opioid drugs. As with 
alcohol (see box ‘Cocaine and alcohol’), heroin changes the 
pattern of cocaine use and the frequency of injection may 
increase because of cocaine’s short half-life. Consequently, 
the health risks related to injecting, such as contracting human 
immunodefi ciency virus (HIV) or other blood-borne infectious 
diseases, increase (Leri et al., 2003).
The cardiovascular effects of cocaine are amplifi ed when 
it is co-administered with opioids. Studies on laboratory 
animals indicate that morphine may enhance the toxic 
potential of cocaine and that cocaine, like morphine, 
induces respiratory depression (Hardman et al., 1996), 
possibly contributing to the ultimate mechanism of death 
in narcotic overdose cases (Polettini et al., 2005; 
Tseng et al., 1991).
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structural defects in the vascular endothelial cell barrier, 
which subsequently increases permeability to peroxidase and 
low-density lipoproteins (Brownlow and Pappachan, 2002).
Neurological complications
Acute and chronic cocaine use may cause either ischaemic 
or haemorrhagic stroke (cerebrovascular accident) — 
an acute neurological condition in which the blood supply to 
a part of the brain, commonly arterial, but possibly venous, is 
interrupted.
Cocaine-related seizures (temporary abnormal 
electrophysiological phenomena of the brain, resulting in 
abnormal synchronisation of electrical neuronal activity) 
occur most often after chronic use, but also may occur after 
the initial use of cocaine via any route of administration. 
Most cocaine-related seizures occur within minutes of 
drug use, and almost always within 90 minutes (peak 
concentration) (Boghdadi and Henning, 1997). Cocaine-
induced seizures are usually single, generalised, tonic-
clonic seizures. However, multiple seizures and even status 
epilepticus can occur after cocaine use.
Cocaine-induced seizures can occur in patients with or without 
a history of seizure disorder. The prevalence of cocaine-
induced seizures is twice as high in subjects with a history of 
non-cocaine-related seizures than in those without a history of 
seizure disorder. Seizures caused by cocaine may be lethal, 
primarily because of associated cocaine-induced hyperthermia, 
systemic acidosis, cardiac dysrhythmias and cardiac arrest.
Responses to and interventions 
in cocaine and crack cocaine use
Cocaine treatment and harm reduction
The provision of specialised and tailored treatment, as well 
as harm-reduction programmes, for problematic cocaine and 
crack cocaine users in Europe is limited. Several countries, 
where the prevalence of powder cocaine use is high, are 
increasingly acknowledging the importance of providing 
adequate and evidence-based services for problematic 
cocaine and crack cocaine users and commissioning new 
research into the development of effective treatments for 
cocaine dependence (Germany, Ireland, Spain, Italy, 
the Netherlands and the United Kingdom). In contrast, in 
countries where the prevalence of cocaine or crack cocaine 
use is relatively low and thus there is little treatment demand, 
national reports indicate that specific cocaine treatment 
services do not constitute a policy priority (Estonia, Greece, 
Slovakia, Finland and Norway). Moreover, Europe faces 
the challenge of providing adequate services to a broad 
spectrum of users seeking treatment: socially integrated 
powder cocaine users, who are usually characterised 
by a more recreational consumption pattern; problem 
cocaine users with a history of concomitant heroin use or in 
substitution treatment; and highly marginalised crack cocaine 
users. In addition, cocaine- and crack-dependent users 
rarely use only cocaine and, rather, show a problematic 
use of several substances, mainly alcohol, cannabis and 
opioids. These factors have an important impact on overall 
treatment outcomes. The diverse nature of cocaine problems 
underlines the need to provide professionals working in 
this area with both a better understanding of the evidence 
base for interventions and training on how to better respond 
to cocaine problems and problems caused by the use of 
cocaine in combination with other drugs.
Cocaine (and crack cocaine): a difficult drug to treat
There is an overall consensus in the literature that the 
treatment of cocaine and crack cocaine dependence is 
associated with high attrition and relapse rates (e.g. NTA, 
2007; Sayre et al., 2002) (51). One reason for this might be 
that no viable effective pharmacological therapeutic agent is 
available to help clients to manage cocaine abstinence and 
reduce the strong cravings experienced during this period. 
As is the case for opioid treatment, effective pharmacological 
agents integrated within a psychosocial and supportive 
treatment programme would be most beneficial for treatment 
compliance and maintaining abstinence.
Ensuring adequate provision of cocaine treatment must take 
into account the fact that cocaine and crack cocaine users 
constitute a heterogeneous population with different needs. 
Primary cocaine users and recreational powder cocaine 
users are usually socially integrated, with stable living 
conditions and a regular income (see ‘Treatment demand 
data’). In Europe, due to the lack of established cocaine 
treatment programmes, cocaine treatment usually takes 
place in traditional outpatient settings tailored for opioid 
users. Recreational users and primary cocaine users seeking 
treatment might therefore be reluctant to initiate or continue 
treatment as they do not identify themselves with the opioid 
clients in treatment in these settings. A recent Irish pilot 
project on cocaine treatment found that outpatient facilities 
could circumvent cocaine users’ reluctance to attend the more 
opioid-oriented day programmes by providing access to 
cocaine users during evenings. Furthermore, outreach work 
(51) An in-depth literature review on the treatment of problem cocaine use is available at http://www.emcdda.europa.eu/?nnodeid=18945
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was conducted immediately before and after the weekend as 
these times correspond to periods of increased cocaine use 
(NACD, 2007). Such interventions are thought to increase 
the attractiveness of existing treatment services for a larger 
number of problematic powder cocaine users.
A substantial number of cocaine-dependent users are also 
heroin users or in substitution treatment, with treatment 
usually focusing mainly on the opioid problem (Gossop et 
al., 2002; Molinaro et al., 2006; Prinzleve et al., 2004; 
Puigdollers et al., 2004; SIVZ/IVZ, 2006). Thus, continued 
cocaine use by clients in substitution treatment may interfere 
with the treatment programme and subsequently jeopardise 
the overall treatment outcome (DeMaria et al., 2000; 
Rowan-Szal et al., 2000). Similarly, the co-use of alcohol 
and co-morbid psychiatric and personality disorders (e.g. 
aggression, acute psychosis and paranoid behaviour), often 
observed in cocaine-dependent users, also constitute major 
problems for staff and clinicians trying to address clients’ 
cocaine dependence (EMCDDA, 2007).
Finally, use of crack cocaine is more prevalent among 
more marginalised and deprived populations (e.g. the 
homeless and sex workers), who are more difficult to reach 
and who might seek treatment only at a much later stage of 
their dependence when they may be more difficult to treat. 
However, as noted above, crack cocaine problems are 
relatively rare in Europe. Some countries report that crack 
cocaine use may cause particular problems among some 
specific ethnic populations; in such cases, culturally sensitive 
interventions will be needed.
All the abovementioned factors (heterogeneity of the cocaine 
population, polydrug use, cultural diversity) require flexible 
and attractive treatment services, as well as adequate staff 
training and expertise in cocaine treatment, and this is even 
more so for treatment of multiple substance use. Recent 
experimental trials have shown promising results for some 
pharmacological therapeutic agents (e.g. Topiramate and 
cocaine vaccine), with psychosocial interventions being 
the most effective responses to problem cocaine use with 
associated mental health problems. These evidence-based 
interventions are mainly based on cognitive behavioural 
approaches, such as cognitive behavioural therapy (CBT), 
motivational interviewing and a community reinforcement 
approach combined with contingency management 
(e.g. voucher-based incentives).
Pharmacological treatment
In the absence of pharmacological options for assisting the 
user to maintain abstinence or reduce cocaine use, most 
prescribing is aimed at providing symptomatic relief. Cocaine 
and crack cocaine users who are undergoing treatment are 
often treated with medications, such as antidepressants, 
benzodiazepines and antipsychotics, primarily to reduce the 
negative symptoms associated with cocaine abstinence or 
withdrawal, such as depression and anxiety. The development 
of agents that may actively assist the user to achieve or 
maintain abstinence is still at the experimental stage and work 
in this area is largely based on the dopamine hypothesis of 
cocaine’s action (Dackis and O’Brien, 2001). Essentially, 
molecules are considered potential therapeutic agents 
when they either increase dopamine release, thus reducing 
withdrawal symptoms and cocaine craving (e.g. dopamine 
agonists, substitution treatment), or decrease dopaminergic 
activity (dopamine antagonists, gamma-aminobutyric acid-
(GABA)ergic enhancers). Inhibiting dopaminergic activity 
when using cocaine should theoretically be associated with 
a reduction in the positive subjective effects of cocaine and 
thereby decrease the pleasure experienced when consuming 
the drug. Thus, baclofen, tiagabine and Topiramate have 
shown to mediate dopaminergic activity by increasing 
GABAergic transmission, which, through inhibitory 
mechanisms, results in a decrease in dopamine release. 
These three drugs have shown promising therapeutic 
potential in preclinical and controlled clinical trials.
Similarly, Modafinil, a medication that blunts cocaine 
euphoria under controlled conditions, has been reported to 
significantly reduce cocaine use compared to placebo controls 
in a double-blind controlled clinical trial in conjunction with 
CBT (Dackis et al., 2005). Some studies have also suggested 
that disulfiram, also known as Antabuse and well known for its 
therapeutic effects in alcoholism, may have positive effects in 
the treatment of cocaine dependence, especially in cocaine-
dependent users with co-morbid alcohol problems.
A novel approach to cocaine treatment currently being tested 
uses the body’s own immune system. A cocaine vaccine 
(TA-CD) is administered to cocaine users wanting to remain 
abstinent, which in simple terms can block the action of the 
drug. The immunotherapy is designed for the use of patients 
who are already dependent rather than as a prophylactic 
immunisation, which would aim to prevent dependency 
occurring by immunising the individual before they were 
exposed to the drug. Once administered, the TA-CD cocaine 
vaccine induces the production of cocaine antibodies, which 
bind to cocaine molecules in the bloodstream and thereby 
allow naturally occurring enzymes to convert the cocaine 
molecules into inactive molecules (Martell et al., 2005). 
By preventing cocaine molecules from reaching the brain, 
the vaccine blocks the euphoric effects of cocaine and 
thereby reduces its reinforcing properties and, theoretically, 
its continued use. The results of the initial clinical trials are 
encouraging when compared with other pharmacological 
strategies, and further studies are required to test the viability 
of the cocaine vaccine as a pharmacotherapy for cocaine 
dependence. This type of approach is unlikely to provide 
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a ‘magic bullet’ for treating cocaine problems but does 
appear to have promise and may provide a useful addition 
to the clinical options available in the future. Furthermore, 
although the development of effective pharmacological 
agents in this area is urgently required, a general lesson 
from the experience of treating other types of drug problem 
is that they are likely to be most effective if accompanied by 
appropriate psychosocial interventions and support.
Psychosocial treatment
Cocaine is a potent reinforcing drug, and dependent cocaine 
users are characterised by a loss of control over 
their consumption, with damaging physical, mental and 
social consequences (Dackis and O’Brien, 2001). 
Therefore, the aim of psychosocial treatments is to support 
individuals in making changes in their substance-using 
behaviours and to address the individual’s mental health 
problems. To date, among the interventions that have shown 
the most promising results in addressing these two issues in 
relation to cocaine dependence, and which will be the main 
focus of this section, are cognitive behavioural interventions 
that focus on the identification of cognitive and environmental 
factors controlling problem behaviour, and the development 
or rehearsal of skills required to achieve changes in that 
behaviour (Wanigaratne et al., 2005).
Psychosocial cocaine treatment in Europe
Cognitive behavioural interventions were identified in a 
recent EMCDDA literature review of the treatment of cocaine 
dependence as having the most robust evidence base as an 
effective way of reducing and preventing future cocaine use 
(EMCDDA, 2007). However, it was also noted that most 
evaluations in this area have been conducted in the USA and 
research on this topic in Europe remains scarce; therefore, 
the extent to which these findings are directly transferable to 
the European treatment context is questionable. Nonetheless, 
CBT or similar cognitive behavioural approaches are widely 
offered in Europe, although professionals are usually not 
specifically trained to treat cocaine dependence (EMCDDA, 
2007). CBT is based upon social learning principles and 
aims at helping patients to develop alternative behaviours 
at the expense of behaviours associated with cocaine use. 
Briefly, CBT consists in enhancing the patient’s motivation 
to stop cocaine use; teaching skills to cope with high-risk 
situations in which patients are most likely to use cocaine; 
identifying and reducing habits associated with cocaine use 
and replacing them with longer-lasting rewarding activities; 
teaching users how to manage painful effects (e.g. cravings, 
depression); and helping patients to improve interpersonal 
functioning and enhance social supports (Rounsaville and 
Carroll, 1992). It is argued that an important advantage 
of CBT compared with other approaches, such as the 
12-step programme or psychoanalytical therapy, is that it 
combines interventions on substance-related behaviours 
with interventions aimed at addressing associated mental 
health problems (e.g. depression, anxiety), which are often 
observed in cocaine and crack cocaine users undergoing 
treatment (Carroll et al., 1995).
Member States where prevalence levels of cocaine use are 
high are now working towards the development of effective 
interventions. This requires the development of programmes 
based on the existing evidence base and commissioning 
studies to evaluate their effectiveness. In addition, work is 
required to identify the needs of those with cocaine problems 
and ensure that services meet quality management standards. 
In Denmark, for example, the Copenhagen municipality 
has allocated funds to the development of a high-quality 
treatment programme that will implement a treatment model 
for substance dependence, including cocaine dependence, 
based on cognitive behavioural approaches (cognitive group 
and individual therapy and motivational interviewing). The 
project will be evaluated against specific quality targets. In 
addition, a series of pilot projects were recently conducted in 
Ireland to train professional counsellors working with cocaine 
users to deliver intensive CBT-based interventions (NACD, 
2007).
In Germany, a series of services with specialised outpatient 
services, such as KOKON or the Seehaus-Projekt, offer 
interventions to problematic cocaine users within a two-phase 
approach, with the initial phase focusing on treating cocaine-
related problems with a cognitive behavioural approach, 
while the second phase consists of a non-substance-specific 
phase of further consolidation through CBT. In Spain, where 
cocaine treatment demand is the highest in Europe, clinicians 
most frequently adopt a CBT-based approach, usually a 
relapse prevention model based on the work of Marlatt and 
Gordon, which involves cognitive restructuring, increasing 
the client’s self-efficacy and learning problem-resolution skills. 
Prochaska and DiClemente’s change process model, another 
CBT-based approach frequently used in Spain, matches 
treatment strategies with the patient’s stage of motivation 
and readiness for change (Pedrero Pérez and Puerta Garcia, 
2001). In Italy, a non-comparative study based on an 
outpatient cocaine treatment programme named ’Programma 
Conoscenza’ involved a first phase of short motivational 
interviews, which was followed by a longer CBT-based 
intervention for an average of 9 to 14 months (Leopardi et al., 
2006). Out of the initial 96 patients taking part in ‘Programma 
Conoscenza’, 68 adhered to the treatment, 6 were transferred 
to another service and 22 patients dropped out. Some 77 % 
of patients’ urine samples were cocaine free at the end of the 
programme and 60 % of patients reported having significantly 
improved their cocaine problem.
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Another form of behavioural intervention that has shown 
some evidence of effectiveness, in US studies, for cocaine 
dependence is the community reinforcement approach (CRA). 
CRA is a multifaceted behavioural treatment that includes a 
range of interventions, including family counselling, stress 
management, social skills training and job counselling 
(Peele and DeGrandpre, 1998). These specific types of 
counselling and skills training are tailored to the treatment 
goals of the client, with individuals having their own positive 
reinforcers in the community (e.g. social or family activities), 
which maintain their abstinent behaviour (NTA, 2002). 
In the Netherlands, a controlled trial of CRA for cocaine 
users (with or without heroin addiction and in or out of 
methadone maintenance treatment) is reported to be in its 
final phase. The study is currently testing the applicability 
and effectiveness of CRA combined with voucher incentives 
in the Dutch situation. The CRA is often, but not always, 
combined with contingency management (CM), an incentive-
based approach (e.g. Higgins et al., 2003). Rewards are 
offered to patients contingent on cocaine-free urine samples 
or positive treatment behaviours (e.g. attendance) and 
relatively promising results have been reported from the USA, 
concerning both retention and abstinence rates (Higgins et 
al., 1993, 2003; Lewis and Petry, 2005). Rewards can be, 
for example, vouchers for acupuncture sessions or financial 
incentives. For example, Higgins et al. (1993, 2003) found 
an increased retention rate for combined therapy, compared 
with vouchers-only therapy and 12-step counselling in 
cocaine-dependent users. Moreover, incentives could be 
particularly relevant for more deprived substance-abusing 
populations such as crack cocaine users or opioid users co-
abusing cocaine. Henskens (2004) conducted a randomised 
controlled trial of the effectiveness of a novel outreach 
treatment programme for severe crack cocaine users in the 
Netherlands and found that incentives (acupuncture sessions 
and walk-in services) and a positive relationship with care 
providers were directly associated with treatment retention.
Treatment of severe cocaine or crack cocaine dependence 
in marginalised populations
The effectiveness of cognitive behavioural approaches in the 
treatment of drug dependence requires a certain degree of 
normal cognitive functioning and the willingness and ability 
to make drastic changes in one’s lifestyle. This raises the 
question of how appropriate such approaches will be in 
addressing the needs of those with cocaine or crack cocaine 
problems who have a highly marginalised lifestyle, often 
with severe health, psychological and criminal problems. 
Henskens (2004) evaluated a novel crack cocaine outreach 
programme that was community based and consisted of 
assertive outreach and case management while putting 
strong emphasis on the client–therapist relationship. Patients 
in the treatment group reported elevated levels of satisfaction 
with their treatment and showed significant improvements 
in physical health, general living conditions and psychiatric 
status compared with clients who received standard 
treatment.
In the United Kingdom, guidelines issued to professionals 
working with severe cocaine and crack cocaine users 
suggested that long-stay residential care (three months or 
more) would be appropriate for particularly needy clients, 
such as homeless crack cocaine users (NTA, 2002). The 
benefits of residential care for marginalised crack cocaine 
and cocaine users may lie in the temporary detachment from 
the highly detrimental environment that is often associated 
with crack cocaine use (e.g. violence and lack of healthcare). 
Thus, a recent evaluation of four UK specialist crack cocaine 
and stimulant drug treatment services revealed that crack 
cocaine clients in residential service complied with the 
treatment regime, reported benefits in terms of their self-rated 
health and motivation, and achieved abstinence during 
their admission (NTA, 2007). However, the same study also 
observed that drop-out rates were extremely high across all 
services (residential and outpatient), referral sources such 
as other drug services or criminal justice were negatively 
associated with treatment retention, and women could be put 
off engaging in treatment due to the lack of childcare within 
treatment settings and fear of retaliation from exploitative or 
coercive male partners.
In summary, despite the increasing number of cocaine 
treatment demands, specialised cocaine treatment provision 
remains scarce and many dependent cocaine users are being 
treated within outpatient facilities, which may be more focused 
on responding to the needs of clients with opioid problems. 
This situation may be beginning to change, particularly in 
those countries with significant cocaine-using populations. 
Although the evidence in this area is largely based on the US 
experience, EU Member States are gradually acknowledging 
the importance of conducting national and local research 
studies and evaluations. There is also a growing recognition 
of the need to develop treatment provision for the needs 
of a heterogeneous cocaine-using population. 
A consensus is growing that recognises the value of cognitive 
behavioural approaches for treating cocaine problems 
generally in outpatient settings with services that are attractive 
to their target population. There is also acknowledgement 
that, beyond this, the needs of chronic and marginalised 
cocaine users may differ, and this group may be particularly 
challenging for treatment services to engage with and require 
more intensive interventions, possibly including the option of 
residential care.
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Harm reduction
Cocaine and crack cocaine use is associated with a variety 
of high-risk behaviours with harmful consequences which 
differ according to the pattern of use, route of administration 
and social circumstances of the user. For example, 
recreational use of cocaine, which frequently occurs in 
nightlife settings, is associated with increased health risks 
such as acute physical problems (see ‘Medical problems 
related to cocaine use’, above), chronic psychological 
distress (e.g. depression, anger and impulsiveness) and 
infections through sharing of snorting equipment (snorting 
straws and banknotes) — although such risks are thought 
to be relatively low (Galperim et al., 2004; McMahon et 
al., 2004). Excessive cocaine use has also been reported 
to be indirectly associated with high-risk sexual behaviour 
(e.g. higher likelihood of unprotected sex, especially in 
combination with excessive alcohol consumption) (e.g. 
Castilla et al., 1999). In most European countries, advice 
and harm-reduction services offer information on the risks 
associated with drug use in general, usually including 
material on the risks associated with acute and chronic 
cocaine consumption. Advice may be offered through a 
number of different media, allowing users to understand the 
dangers of different behaviours and promoting strategies that 
would allow them to reduce the risks they face. For example, 
the European Foundation of Drug Helplines, which offers 
advice and information to drug users, reports an increase 
in the number of calls related to cocaine during recent 
years (52). The Belgian Flemish telephone helpline DrugLijn 
reported that 17 % of contacts in 2004 concerned cocaine, 
compared with only 10 % in 2000, and 27 % of these 
contacts originated from users, 30 % from parents and the 
remainder from friends, partners, family members and others. 
Furthermore, compared with the total group of contacts, 
questions about cocaine originated more often from 25- to 
35-year-olds (Evenepoel, 2005).
Studies have shown that high-risk sex behaviours that may 
lead to transmission of infectious diseases are often more 
common among severely dependent crack cocaine-using 
women. This group is highly marginalised and members 
may be engaging in sex work to pay for their compulsive 
and costly drug habit. The group has been targeted by 
outreach and harm-reduction services. For example, in the 
Netherlands, municipal health services have implemented 
special health programmes targeting crack cocaine-using 
sex workers, while in France, the association Espoir Goutte 
d’Or, which focuses on risk prevention and harm reduction 
for crack cocaine users, organises voluntary counselling on a 
weekly basis and rapid testing for HIV and hepatitis. It also 
distributes condoms and disposable crack cocaine pipes, 
and provides information on safer drug use.
Furthermore, although injecting has become less popular 
among the drug-using population, a non-negligible 
proportion of cocaine users (nearly 10 % of clients in 
treatment (53); De la Fuente et al., 2006) still choose this 
route of administration for their cocaine consumption, often 
in combination with heroin (‘speedballing’). Consequently, 
most Member States provide cocaine-injecting users with 
the same services and facilities as those provided to opioid 
users, such as safe use recommendations, safe injecting 
training and needle exchange programmes. Cocaine users 
can also use supervised consumption rooms in Germany, 
Spain, Luxembourg and the Netherlands, but not in Norway. 
Furthermore, in the German cities of Hamburg and Frankfurt, 
inhalation rooms for crack cocaine smokers have been 
implemented to reduce the risks associated with consumption 
through inhalation. Finally, as mentioned earlier, severe 
cocaine and crack cocaine dependence is characterised 
by exaggerated compulsive consumption behaviour, 
and users continuously suffer from restlessness, extreme 
tension, paranoia and physical exhaustion. In response, the 
Ganslwirt outpatient service in Vienna provides a resting room 
where cocaine and crack cocaine users can relax in a calm 
environment, although they may not consume. The same service 
also provides safe use recommendations and can serve as a 
starting point for further interventions. Similar ’chill-out’ rooms or 
daytime resting rooms are also provided in Barcelona, Hamburg 
and Frankfurt. For example, in Frankfurt and in Hamburg, special 
resting rooms with day-sleeping beds primarily for crack cocaine 
users are integrated within a low-threshold drug help centre, 
which also provides counselling, medical and psychiatric help, a 
consumption room and a shelter.
Policies and strategies in response 
to cocaine use
Strategies and action plans targeting a specific substance are 
rare in the EU, where comprehensive approaches, sometimes 
covering both licit and illicit substances, are common. 
However, when a certain level of problems is observed or 
perceived, substance-specific strategies or plans can be 
developed, usually for a limited time. An example of such 
is the national crack plan (2002) in England (Home Office, 
2002), which was followed a few years later by a crack 
cocaine strategy (2005–08) for London (GLADA, 2004). Both 
are responses to an increase in use and problems related to 
this substance and include extended measures to reduce crack 
cocaine trafficking and to help those who are using this drug.
(52) http://www.fesat.org
(53)  See Table TDI-17 (part ii) and (part vi) in the 2007 statistical bulletin.
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Another example is Ireland, where a report on cocaine use 
published by the National Advisory Committee on Drugs 
(2003) was followed by a set of specific recommendations 
and funding proposals developed by the Irish national 
drugs strategy team. More recently, an intersectoral crack 
cocaine strategy group is looking at ways to respond to crack 
cocaine-related problems in Dublin.
The Dutch action plan for drug trafficking at Schipol airport, 
which was started in 2002, was developed to combat 
cocaine smuggling into the Netherlands and the EU. The two 
main elements of this plan are an intensification of passenger 
controls and a better implementation of judicial measures.
Law enforcement activities targeting 
cocaine trafficking in Europe
At European level, Project COLA, run by Europol, targets Latin 
American and associated criminal groups operating towards 
and within the EU and engaged primarily in the trafficking of 
cocaine. It provides operational support to live investigations 
in participating Member States and enhances the strategic 
intelligence picture. It is complemented by the Europol Cocaine 
Logo System, which collates modus operandi, photographic and 
other information on cocaine seizures and on logos/markings 
on the drugs and their packaging, in order to identify matches 
between seizures and promote international law enforcement 
cooperation and information exchange (Europol, 2006).
At national level, it seems that most European countries have 
set up supply reduction activities that target illicit drugs in 
general, and specific measures against cocaine trafficking 
are therefore rare.
In Ireland, Operation Plaza was set up in 2006 by the 
Garda National Drugs Unit to respond to the sale and supply 
of cocaine and crack cocaine in inner-city Dublin; it enabled 
identification of the main players in both the Irish and 
immigrant communities involved in this criminality.
Portugal, which is one of the main entry points for cocaine 
coming into Europe, has been running widespread network 
investigations, notably by using key informants in strategic 
countries such as Brazil and Cape Verde; this has been 
complemented by seizures of assets (money and property) 
linked to cocaine trafficking.
As part of the 2002 action plan for drug trafficking at 
Schipol airport, the Netherlands has set up 100 % control 
on flights from high-risk countries for cocaine importation, 
such as the Netherlands Antilles, Aruba, Suriname, 
Venezuela and the Dominican Republic. As a result, an 
average of 175 couriers were arrested each month in 2005 
and 16 cases of organised crime were investigated at the 
airport during 2005 to mid-2006. A body scan is used 
to detect swallowed drugs. In addition, a special law court 
with prison facilities has been set up at the airport. Cocaine 
couriers who are caught but not prosecuted are named on 
a ’black list’, which is then circulated to other countries and 
airlines, in particular through the Schengen information 
system, to stop them re-entering the Netherlands. In addition, 
preventative measures (controls, radar, body scans) have 
been implemented in departing countries. It seems likely that 
relaxation of 100 % control and the overseas controls at the 
Antilles would result in an increase in the inflow of couriers.
In the United Kingdom, as part of the national crack 
plan (2002), toolkits have been developed to enable the 
disruption of crack cocaine markets and distributed to the 
police, crime and disorder reduction partnerships, drug and 
alcohol action teams and other law enforcement agencies. In 
addition, Operation Crackdown, launched in 2005, targeted 
local class-A drug markets: during the three-month operation, 
police forces closed 170 crack houses, disrupted local drug 
markets, seized illegal firearms, charged drug suppliers and 
seized several million euros in cash assets.
International action against the trafficking of 
potassium permanganate
The prevention of the diversion of potassium permanganate (54) 
from licit trade for use in the illicit manufacture of cocaine is now 
covered by the international ‘Operation Cohesion’. Between 
November 2005 and October 2006, 20 exporting countries/
territories provided 966 pre-export notifications to 113 importing 
countries/territories, involving 19 151 tonnes of potassium 
permanganate. In 2005, global potassium permanganate 
seizures were the largest ever reported to the International 
Narcotics Control Board (INCB), with 16 countries intercepting 
183 tonnes. Of the 1.6 tonnes of permanganate potassium 
seized in Europe, Russia once more accounted for the highest 
quantity, followed by Romania and Bulgaria (INCB, 2007b).
(54) A precursor used in the manufacture of cocaine and scheduled under Table I of the 1988 convention.
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